FX.co ★ Cognizant Expands Partnership With Gilead Sciences To Enhance Efficiency And AI Integration

Cognizant (CTSH) announced on Thursday that it is broadening its enduring partnership with Gilead Sciences (GILD) to boost cost efficiency and productivity. This enhanced collaboration will employ machine learning and generative AI to optimize customer service, improve employee interactions, and streamline business operations. The initiative aims to bolster Gilead's focus on life-saving treatments by integrating Cognizant's Neuro AI platform, which is expected to accelerate value creation, streamline IT processes, and enhance operational efficiencies. These improvements are anticipated to result in cost savings that can be redirected to Gilead's core business endeavors. Cognizant is focused on refining user experiences through the deployment of tailored AI solutions, transforming IT services for improved efficiency. As of premarket trading, CTSH is at $82.73, reflecting a 1.90% increase or a rise of $1.54 on the Nasdaq. Meanwhile, GILD is trading at $96.25, marking a 0.66% rise or an increase of $0.69 on the Nasdaq.